Life Sciences

Welcome to HS Life Sciences
Display Name
HS Life Sciences
Banner Image
Image

Dr. McNally has an extensive background in bioanalytical assay development and program leadership spanning nearly 20 years working in the pharmaceutical and biotechnology industry.

After completing her MD PhD at the University of Geneva Medical School, Claire did a postdoctoral fellowship at Harvard University studying key regulators of pancreatic beta cell development and regeneration. In 2010, Claire transitioned to industry joining Merrimack Pharmaceuticals in Cambridge, MA to advance their anti-EGFR program in oncology. In 2013, Claire joined Novartis leading the cross-functional team for Switzerland developing strategic imperatives in development, medical affairs, market access and commercial strategy with a focus on orphan drugs in rare diseases.

Marc Pallardy, Pharm D 1982, PhD in Toxicology 1987, Full professor and Head of the Department of Toxicology (Faculty of Pharmacy, University of Paris-Saclay) since 1997.  Marc is currently Dean of the Faculty of Pharmacy, University Paris-Saclay (since 2015) and Head of the Team 2 “Drug and Chemical Allergy, Immunotoxicology and Immunopathology”, INSERM UMR 996.

As a Senior Principal Scientist in the translational immunology group in pre-clinical safety (PCS) Dr. Hannah Morgan is a specialist in the in vitro assessment of biotherapeutic-induced immune related adverse events with a particular focus on immunogenicity.

Dr. McNally has an extensive background in bioanalytical assay development and program leadership spanning nearly 20 years working in the pharmaceutical and biotechnology industry.

Marc Pallardy, Pharm D 1982, PhD in Toxicology 1987, Full professor and Head of the Department of Toxicology (Faculty of Pharmacy, University of Paris-Saclay) since 1997.  Marc is currently Dean of the Faculty of Pharmacy, University Paris-Saclay (since 2015) and Head of the Team 2 “Drug and Chemical Allergy, Immunotoxicology and Immunopathology”, INSERM UMR 996.

After completing her MD PhD at the University of Geneva Medical School, Claire did a postdoctoral fellowship at Harvard University studying key regulators of pancreatic beta cell development and regeneration. In 2010, Claire transitioned to industry joining Merrimack Pharmaceuticals in Cambridge, MA to advance their anti-EGFR program in oncology. In 2013, Claire joined Novartis leading the cross-functional team for Switzerland developing strategic imperatives in development, medical affairs, market access and commercial strategy with a focus on orphan drugs in rare diseases.

View: Translational Medicine at Novartis Institutes for BioMedical Research (NIBR)

In this video series, Novartis Institutes for Biomedical Research (NIBR) explains their approach for early drug development, called ‘Translational Medicine’. This includes an introduction into the role of Translational Medicine, as well as corresponding videos for the offered webinars.

 

The Role of Translational Medicine at Novartis Institutes for BioMedical Research (NIBR)

 

 

Immunogenicity